Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma

Conditions: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma Interventions: Drug: Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection Sponsors: Peking University; Gracell Biopharmaceuticals, Inc. Recruiting

https://clinicaltrials.gov/study/NCT06353152

Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials

More News: Adenocarcinoma | Gastric (Stomach) Cancer | Gastroenterology | Research